China Microarray Market Size, Share, Forecast, & Trend Analysis
Meticulous Research®—a
leading global market research company, published a research report titled, ‘China
Microarray Market -Global Opportunity Analysis and Industry Forecast
(2024-2031)’. According to this latest publication from Meticulous Research®,
the China microarray market is expected to register a CAGR of 8.4% from 2024 to
reach $910.4 million by 2031.
The growth of the
China microarray market is driven by the increasing application of microarrays
for research purposes, the growth in genomics & proteomics uses, the
growing number of cancer cases and genetic conditions, and growing R&D
expenditures by the pharmaceutical & biotechnology industries. Furthermore,
advancements in microarray technology and the increasing need for personalized
medicine create substantial growth opportunities for the China microarray
market players.
However, the higher
costs of microarrays compared to other genetic testing methods and the growing
utilization of Next-generation Sequencing (NGS) technology are expected to
hinder the growth of this market. Microarrays' lack of sensitivity and accuracy
is a major challenge impacting market growth.
Key Players
The key players
operating in China microarray market are Sino Biological, Inc. (China),
CapitalBio Technology Co., Ltd. (China), Arrayit Corporation (U.S.), Thermo
Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), Revvity, Inc. (U.S.),
Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), and Qiagen N.V.
(Netherlands), and RayBiotech Life, Inc. (U.S.).
By product, the consumables segment is predicted to hold
the largest market share of 62.6% in 2024. This segment’s major market share is
due to the recurring use of assays & kits in identifying the causes of
various chronic conditions, the wide availability of consumables for disease
diagnosis, and the growing implementation of point-of-care testing kits. In
addition, key market players are focusing on various growth strategies, such as
product launches and strategic agreements, to strengthen their market positions.
For instance, in March 2024, QIAGEN N.V. (Netherlands) launched QIAstat-Dx
Analyzer 2.0, an upgrade of the previous analyzer that allows users to view,
comment on, and confirm diagnostic test results from desktops or mobile
devices.
By application, the drug discovery & development segment
is expected to dominate in 2024, with a 51.7% share in the China microarray
market. This segment's large market share is attributed to the rising incidence
of infectious diseases, the growing use of DNA, RNA, and protein analysis for
disease diagnosis, and the growing R&D expenditure and initiatives to
increase research capacity by introducing new research centers due to advanced
technologies.
By end user, in 2024, the pharmaceutical and biotechnology
companies segment is projected to make up the largest share of the China
microarray market. This segment's large market share is attributed to the
growing emphasis on drug discovery and development, the identification of
individuals with similar genetic makeup, the in-depth understanding of diseases
and their drug responses, rising awareness of precision medicine, and rising
pharmaceutical R&D expenditure.
Download Sample
Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=6004
Key Questions
Answered in the Report:
- What are the high-growth market segments
in terms of product, application, and end user?
- What was the historical market for China
microarray across the globe?
- What are the market forecasts and
estimates for the period 2024–2031?
- What are the major drivers, restraints,
challenges, and opportunities in the China microarray market?
- Who are the major players in the China
microarray market?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment